Vermillion Inc (NASDAQ:VRML) Stock Is Shorted Less

June 14, 2018 - By Clifton Ray

Investors sentiment decreased to 0.78 in Q1 2018. Its down 0.10, from 0.88 in 2017Q4. It fall, as 2 investors sold Vermillion, Inc. shares while 7 reduced holdings. 3 funds opened positions while 4 raised stakes. 19.93 million shares or 4.10% less from 20.78 million shares in 2017Q4 were reported.
3,807 were accumulated by Tower Cap Limited (Trc). The Massachusetts-based Fmr Limited Com has invested 0% in Vermillion, Inc. (NASDAQ:VRML). Greenwich Wealth Management Ltd Liability Corporation stated it has 0.04% in Vermillion, Inc. (NASDAQ:VRML). California Employees Retirement System reported 54,500 shares or 0% of all its holdings. Geode Capital Mngmt Ltd Liability Corporation has invested 0% in Vermillion, Inc. (NASDAQ:VRML). 10,157 are held by Susquehanna Gp Ltd Liability Partnership. Morgan Stanley invested in 0% or 27,400 shares. 5 were reported by Royal Bancorporation Of Canada. Hightower Advsrs Limited Liability Corp holds 30,000 shares or 0% of its portfolio. M&T Natl Bank Corporation holds 255,000 shares or 0% of its portfolio. Vanguard Grp reported 1.02M shares stake. Essex Investment Management Ltd Com reported 195,908 shares. Wells Fargo & Mn holds 0% or 15,075 shares in its portfolio. Trellus Mngmt Ltd Liability Corporation invested in 0.29% or 118,922 shares. The New York-based Cannell Peter B Company has invested 0.02% in Vermillion, Inc. (NASDAQ:VRML).

Since April 17, 2018, it had 2 buys, and 0 sales for $4.95 million activity. 2.11 million shares valued at $2.11 million were bought by Schuler Henri George on Tuesday, April 17.

The stock of Vermillion Inc (NASDAQ:VRML) registered a decrease of 29.43% in short interest. VRML’s total short interest was 536,200 shares in June as published by FINRA. Its down 29.43% from 759,800 shares, reported previously. With 145,900 shares average volume, it will take short sellers 4 days to cover their VRML’s short positions. The short interest to Vermillion Inc’s float is 1.87%.

The stock decreased 2.09% or $0.0201 during the last trading session, reaching $0.9399. About 54,393 shares traded. Vermillion, Inc. (NASDAQ:VRML) has declined 44.89% since June 14, 2017 and is downtrending. It has underperformed by 57.46% the S&P500.

Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance outcomes for women in the United States. The company has market cap of $65.83 million. It is developing novel diagnostic tests for gynecologic disease with focus on ovarian cancer. It currently has negative earnings. The company??s products include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor.

More news for Vermillion, Inc. (NASDAQ:VRML) were recently published by: Nasdaq.com, which released: “Vermillion Names Chris Goulart to Senior Vice President of Commercial Operations” on June 13, 2018. Seekingalpha.com‘s article titled: “Premarket analyst action – healthcare” and published on May 24, 2018 is yet another important article.

Vermillion, Inc. (NASDAQ:VRML) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: